Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — Ra Medical Systems — Investor Presentation (September 2020)
25 slides from Catheter Precision's investor presentation, Sep 14, 2020
Slide 1: Ra Medical Systems Corporate Presentation September 2020
Ra Medical Systems, Inc. NYSE: RMED Corporate Presentation September 2020
Slide 2: Disclaimer
Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Ra Medical Systems, Inc. (the “Company”) and involve known and unknown risks, uncertainties and othe
Slide 3: Focused on developing Pharos growth strategy to build on ~$5-6 million annual revenue rate
Focused on developing Pharos growth strategy to build on ~$5-6 million annual revenue rate Highlights Both platforms have established reimbursement in US with favorable economics for physician offices Excimer laser platform with FDA-approved applications addressing Peripheral Artery Disease (PAD) an
Slide 4: DABRA and PHAROS excimer laser technology
DABRA—Excimer laser that utilizes disposable catheters for crossing total chronic occlusions (CTOs) and ablating a channel in occlusive peripheral vascular disease. DABRA is used as a tool to treat peripheral artery disease (PAD), a form of peripheral vascular disease. Photoablation to disintegrate
Slide 5: Up to 200,000 amputations performed annually in the US as a result of PAD
Up to 200,000 amputations performed annually in the US as a result of PAD Disease Burden Peripheral Artery Disease Atherosclerosis of the lower extremities—most commonly in the legs Smoking, genetic predisposition, diabetes, age and obesity may increase risk Characterized by reduced blood flow to su
Slide 6: Large US Addressable Market Opportunity
Large US Addressable Market Opportunity PREVALENCE TREATED PATIENTS MARKET OPPORTUNITY Current US Market Opportunity KEY DRIVER >17 Million PAD Sufferers in the US Only 20–30% of PAD Patients actively treated Annual US TAM Opportunity >$550 million1 For U.S. PAD atherectomy, based on third-party res
Slide 7: DABRA Technology and Mechanism of Action
DABRA Technology and Mechanism of Action DABRA Technology 308 nanometer excimer laser system Unique liquid-filled, full aperture ratio catheter High quality lumen Minimizes mechanical or thermal trauma Mechanism of Action Photoablation Removes blockages by breaking the bonds of the obstructing plaqu
Slide 8: DABRA Advantages
DABRA Advantages Can cross and de-bulk wide variety of plaque Soft thrombus to calcified plaque Tool used by physicians to treat CTOs prior to other alternative treatments Ability to use Above-the-Knee (ATK) and Below-the-Knee (BTK) Monotherapy or adjunct to angioplasty or other treatments Versatile
Slide 9: Clinically Demonstrated Solutions
Clinically Demonstrated Solutions Safety Record Pivotal Study1 Multi-site study at four sites in US and Mexico Enrolled 64 patients with target blockage refractory to guidewire crossing Primary Efficacy Endpoint: Successful crossing of target lesion based on angiographic analysis at time of procedur
Slide 10: DABRA Will Target Office-Based Labs
DABRA Will Target Office-Based Labs We believe our solution expands provider economics Ease of Use Versatility Able to cross and debulk Economics Established Safety and Efficacy
Slide 11: Engineering Efforts Focused on Three Initiatives to Improve DABRA's Performance
Engineering Efforts Focused on Three Initiatives to Improve DABRA’s Performance Extend shelf life 6 months minimum with target 12 months or greater Improve deliverability Develop a catheter with an enhanced outer-jacket to allow physicians to better access difficult anatomy Develop guidewire compati
Slide 12: An FDA-Approved IDE Atherectomy Indication Study is Underway
An FDA-Approved IDE Atherectomy Indication Study is Underway Primary safety endpoint: The incidence of 30-day Major Adverse Events (MAEs) as adjudicated by the Clinical Events Committee (CEC) : All-cause mortality, Unplanned major target limb amputation (at or above the ankle), and/or Clinically dri
Slide 13: Pharos Excimer Laser
Pharos Excimer Laser Psoriasis—chronic autoimmune disorder that causes cells to rapidly accumulate and affects the surface of the skin causing scales and red patches Vitiligo—autoimmune condition causing the skin to turn white due to the loss of pigment from the melanocytes, the cells that produce t
Slide 14: Pharos Science, Advantages and Reimbursement
Pharos Science, Advantages and Reimbursement Pharos Science Same laser platform as DABRA 308-nanometer laser—the center of action spectrum for most immune-mediated inflammatory diseases Does not use heat or ablate lesions—treatments are generally painless Adjustable aiming beam accurately targets on
Slide 15: Fully Operational Manufacturing Facility
Fully Operational Manufacturing Facility Carlsbad, CA Sizable capacity for laser and catheter production 41,000 sq. ft. Carlsbad, CA with three controlled environments manufacturing facility fully staffed and operational Existing facility expected to be capable of manufacturing > 400 lasers/year and
Slide 16: Intellectual Property Portfolio
Intellectual Property Portfolio Patents covering several aspects of the laser systems and delivery device The Company believes that its intellectual property comprises novel and useful inventions that can be protected by patents, and as such, has filed patent applications directed to innovative meth
Slide 17: Executive Team
Executive Team Will McGuire Chief Executive Officer 25 years med-tech experience, including COO of Spectranetics which was acquired by Philips for >$2 billon and CEO of Atheromed, a venture capital-backed peripheral atherectomy company. Also held senior roles at Volcano Corporation, Covidien, and Gu
Slide 18: Financial Overview
Financial Overview
Slide 19: Results of Operations
Six Months Ended Year Ended ($ in thousands) June 30, 2020 Dec. 31, 2019 Vascular Net Revenue $191 $1,275 Dermatology Net Revenue $2,083 $5,924 Total Net Revenue $2,274 $7,199 Gross Profit (Loss) $(477) $(1,651) Operating Expenses: Selling, General and Administrative (Incl. $1.7M and $20.4M stock co
Slide 20: Financial Position
Financial Position ($ in thousands) As of June 30, 2020 As of Dec. 31, 2019 Cash and Cash Equivalents and Short Term Investments1 $29,380 $30,577 Working Capital2 $25,475 $29,186 Total Assets $40,691 $44,081 Equipment Financing $413 $558 Accumulated Deficit $(134,979) $(117,157) Total Stockholders’
Slide 21: Focused on developing Pharos growth strategy to build on ~$5-6 million annual revenue rate
Focused on developing Pharos growth strategy to build on ~$5-6 million annual revenue rate Highlights Both platforms have established reimbursement in US with favorable economics for physician offices Excimer laser platform with FDA-approved applications addressing Peripheral Artery Disease (PAD) an
Slide 22: Key Vascular Milestones
Key Vascular Milestones 2020 2021 2022 * Timing of study enrollment uncertain due to unpredictable ongoing impact of COVID-19 Shelf life root cause identified Catheter with improved deliverability Guidewire compatible catheter Atherectomy indication 510(k) clearance* Enrollment progress in Atherecto
Slide 23: Appendix
Appendix
Slide 24: Reconciliation of Net loss to Adjusted EBITDA
Reconciliation of Net loss to Adjusted EBITDA ($ in thousands) Six Months Ended June 30, 2020 Year Ended Dec. 31, 2019 Statement of Operations Data: Net loss $(17,822) $(56,957) Depreciation and amortization $1,214 $1,750 Interest income $(124) $(1,038) Interest expense $40 $250 Income tax expense -
Slide 25: Board of Directors
Board of Directors Martin Colombatto Chairman. Former VP and General Manager of Broadcom Maurice Buchbinder, MD Interventional Cardiologist Master of Surgery from McGill University William Enquist Former President of Global Endoscopy of Stryker Will McGuire Chief Executive Officer, Ra Medical Former
Ra Medical Systems — Investor Presentation (September 2020) on 6ix